PTC Therapeutics, Inc. Other Current Liabilities
PTC Therapeutics, Inc. (PTCT) had Other Current Liabilities of $1.31 million as of 2022-09-30, per its 10-Q filed 2022-10-27.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2023-02-21
- 2022-09-30: Other Liabilities, Current $1.31M.
- 2022-06-30: Other Liabilities, Current $1.45M.
- 2022-03-31: Other Liabilities, Current $1.45M.
- 2021-12-31: Other Liabilities, Current $1.46M.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2022-09-30 | $1.31M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $1.45M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $1.45M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $1.46M 10-K · filed 2023-02-21 | |
| 2021-09-30 | $1.22M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $1.25M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $1.25M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $1.25M 10-K · filed 2022-02-22 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $4.87M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $3.64M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $3.19M 10-K · filed 2021-02-25 | $8.34M 10-K · filed 2020-03-02 |
| 2019-09-30 | $6.84M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $4.18M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $3.13M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $3.81M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $3.46M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $2.27M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $1.28M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $1.67M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $1.72M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $1.39M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $265.00K 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $865.00K 10-K · filed 2018-03-06 | |
| 2016-09-30 | $257.00K 10-Q · filed 2016-11-03 | |
| 2015-12-31 | $0.00 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |